IIM
KALV

INTECH Investment Management’s KalVista Pharmaceuticals KALV Stock Holding History

INTECH Investment Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,919
Closed -$209K – 2233
2025
Q4 		$209K Hold
12,919
– – ﹤0.01% 1966
2025
Q3 		$157K Sell
12,919
-4,752
-27% -$65.7K ﹤0.01% 2147
2025
Q2 		$200K Sell
17,671
-217
-1% -$2.65K ﹤0.01% 2088
2025
Q1 		$206K Buy
17,888
+684
+4% +$6.98K ﹤0.01% 2080
2024
Q4 		$146K Buy
17,204
+6,349
+58% +$65.8K ﹤0.01% 2124
2024
Q3 		$126K Buy
+10,855
New +$137K ﹤0.01% 1843

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

INTECH Investment Management's KALV Position: Q1 2026 in Review

INTECH Investment Management sold out of KalVista Pharmaceuticals (KALV) in Q1 2026, closing a stake of 12,919 shares — an estimated $209K sold.

INTECH Investment Management first reported a position in KALV in Q3 2024 and held it in 6 quarters. The position peaked at $209K in Q4 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • INTECH Investment Management reported no remaining KalVista Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • INTECH Investment Management sold 12,919 KalVista Pharmaceuticals shares in Q1 2026, an estimated $209K.
  • INTECH Investment Management first reported a position in KalVista Pharmaceuticals in Q3 2024 and held it in 6 quarters.
  • INTECH Investment Management's KalVista Pharmaceuticals position peaked at $209K in Q4 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on INTECH Investment Management's 13F filing for Q1 2026, filed 8 May 2026.